CHAMPIONS ONCOLOGY, INC.
CSBRNasdaq
$6.13
↑ +5.0%Jul 17 close · end-of-day
Price
1Y↓ -21.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$85.1M
Enterprise Value
$78.0M
P/E
—
P/S
1.5
P/B
19.9
EV/EBITDA
—
PEG
—
FCF Yield
4.5%
Dividend Yield
—
Revenue (TTM)
$57.9M
Net Income (TTM)
-$2.3M
Free Cash Flow (TTM)
$3.8M
Gross Margin
—
Operating Margin
-4.5%
Net Margin
-3.9%
ROE
-53.3%
ROIC
—
Debt / Equity
—
Net Cash
$7.1M
Return 1Y
-26.7%
Company profile
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company markets its products through internet, word of mouth, and sales force.
- CEO
- Ronnie Morris
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 230
- Headquarters
- Maryland
- Website
- championsoncology.com
Earnings
CSBR Q3 2026 Earnings
Period ends 2026-01-31
MetricActualYoY
Revenue$16.6M↓ -2.8%
Diluted EPS-$0.02↓ -106.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $41.0M | $49.1M | $53.9M | $50.2M | $56.9M |
| Gross profit | — | — | — | — | — |
| Operating income | $366,000.00 | $607,000.00 | -$5.3M | -$7.4M | $4.6M |
| Net income | $362,000.00 | $548,000.00 | -$5.3M | -$7.3M | $4.7M |
| Diluted EPS | $0.02 | $0.04 | -$0.39 | -$0.54 | $0.33 |
| Operating cash flow | -$1.7M | $6.5M | $4.0M | -$6.1M | $7.4M |
| Free cash flow | -$5.0M | $4.1M | $1.1M | -$7.0M | $7.0M |
| Gross margin | — | — | — | — | — |
| Operating margin | 0.9% | 1.2% | -9.8% | -14.7% | 8.0% |
| Net margin | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.0M | $14.1M | $13.5M | $17.0M | $12.4M | $14.0M | $15.0M | $16.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$272,000.00 | $1.3M | $732,000.00 | $4.5M | -$2.0M | -$527,000.00 | $185,000.00 | -$276,000.00 |
| Net income | -$109,000.00 | $1.3M | $728,000.00 | $4.5M | -$1.8M | -$436,000.00 | $268,000.00 | -$279,000.00 |
| Diluted EPS | -$0.01 | $0.09 | $0.05 | $0.31 | -$0.12 | -$0.03 | $0.02 | -$0.02 |
| Operating cash flow | -$1.8M | $311,000.00 | -$283,000.00 | $490,000.00 | $6.9M | $600,000.00 | -$1.7M | -$1.3M |
| Free cash flow | -$1.8M | $311,000.00 | -$377,000.00 | $448,000.00 | $6.6M | $554,000.00 | -$2.0M | -$1.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1.9% | 9.5% | 5.4% | 26.4% | -16.2% | -3.8% | 1.2% | -1.7% |
| Net margin | -0.8% | 9.3% | 5.4% | 26.4% | -14.9% | -3.1% | 1.8% | -1.7% |
Company news
Mar 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-10-30 | ACKERMAN JOEL | Option exercise | 94,405 | $2.10 | $198,250.50 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.